Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the rationale behind the Phase III MAJIC study (NCT05057494), which is comparing the combination of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.